Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 27 04:00PM ET
2.13
Dollar change
+0.01
Percentage change
0.47
%
Index- P/E- EPS (ttm)-5.74 Insider Own5.59% Shs Outstand24.20M Perf Week26.04%
Market Cap51.55M Forward P/E- EPS next Y-1.24 Insider Trans0.00% Shs Float22.85M Perf Month16.39%
Income-89.08M PEG- EPS next Q-0.36 Inst Own38.10% Short Float0.16% Perf Quarter20.68%
Sales0.00M P/S- EPS this Y72.43% Inst Trans-2.10% Short Ratio0.47 Perf Half Y70.40%
Book/sh3.88 P/B0.55 EPS next Y27.10% ROA-72.53% Short Interest0.04M Perf Year-8.19%
Cash/sh2.46 P/C0.86 EPS next 5Y- ROE-76.66% 52W Range1.07 - 2.95 Perf YTD18.33%
Dividend Est.- P/FCF- EPS past 5Y31.69% ROI-97.45% 52W High-27.80% Beta0.86
Dividend TTM- Quick Ratio21.73 Sales past 5Y0.00% Gross Margin- 52W Low99.07% ATR (14)0.16
Dividend Ex-Date- Current Ratio21.73 EPS Y/Y TTM-113.56% Oper. Margin0.00% RSI (14)70.50 Volatility11.68% 8.66%
Employees17 Debt/Eq0.01 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price15.60
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q52.96% Payout- Rel Volume1.34 Prev Close2.12
Sales Surprise- EPS Surprise24.00% Sales Q/Q- EarningsNov 09 AMC Avg Volume76.56K Price2.13
SMA2022.31% SMA5020.97% SMA20042.22% Trades Volume102,453 Change0.47%
Date Action Analyst Rating Change Price Target Change
May-13-22Resumed Cantor Fitzgerald Overweight $25 → $15
Mar-23-21Initiated Cantor Fitzgerald Overweight $25
Mar-25-24 04:56PM
Mar-21-24 10:31AM
Feb-13-24 07:01PM
Jan-04-24 04:40PM
Dec-04-23 06:00PM
04:05PM Loading…
Nov-29-23 04:05PM
Nov-09-23 04:01PM
Nov-08-23 04:05PM
Nov-02-23 09:05AM
Oct-23-23 07:00AM
Oct-13-23 07:00AM
Oct-02-23 07:00AM
Sep-25-23 07:00AM
Sep-20-23 04:05PM
Sep-11-23 07:00AM
07:00AM Loading…
Sep-06-23 07:00AM
Sep-05-23 07:00AM
Aug-16-23 07:00AM
Aug-10-23 07:00AM
Jul-12-23 07:30AM
Jun-02-23 08:00AM
May-11-23 04:01PM
May-04-23 04:05PM
May-01-23 07:00AM
Apr-05-23 07:46PM
Mar-31-23 06:00AM
Mar-30-23 04:01PM
Mar-23-23 04:05PM
08:00AM
Feb-08-23 04:05PM
08:31AM Loading…
Jan-09-23 08:31AM
08:30AM
Dec-21-22 04:05PM
Nov-14-22 04:01PM
Nov-03-22 04:05PM
Oct-24-22 04:05PM
Oct-03-22 08:00AM
Sep-22-22 04:05PM
Sep-06-22 04:01PM
Aug-29-22 08:00AM
Aug-11-22 04:01PM
Aug-04-22 04:05PM
Aug-01-22 05:00AM
Jul-18-22 08:00AM
Jun-10-22 04:05PM
Jun-09-22 08:00AM
Jun-02-22 04:05PM
12:01PM
May-31-22 06:00AM
May-12-22 04:01PM
May-09-22 08:00AM
May-05-22 04:05PM
May-03-22 04:05PM
Apr-18-22 04:05PM
Apr-14-22 04:05PM
Mar-24-22 04:01PM
12:58PM
Mar-17-22 08:00AM
Feb-14-22 08:00AM
Feb-08-22 04:05PM
Jan-13-22 10:08AM
Dec-27-21 05:17PM
Dec-24-21 06:22AM
Nov-11-21 04:05PM
Nov-04-21 05:34PM
04:05PM
Nov-01-21 08:00AM
Oct-19-21 07:00AM
Oct-07-21 07:51AM
Oct-05-21 04:22PM
Sep-01-21 04:05PM
Aug-12-21 04:01PM
Aug-02-21 08:05AM
Jul-26-21 08:00AM
Jul-02-21 08:00AM
Jun-29-21 04:07PM
Jun-27-21 05:01AM
May-18-21 08:00AM
May-13-21 04:01PM
02:30PM
May-05-21 04:01PM
May-04-21 04:01PM
Apr-26-21 04:05PM
Apr-19-21 04:05PM
Mar-30-21 04:05PM
02:30PM
Mar-29-21 02:08AM
Mar-23-21 08:00AM
Mar-15-21 08:00AM
Mar-02-21 08:00AM
Feb-17-21 08:00AM
Jan-19-21 05:55PM
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The firm's compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential. The CD40L/CD40 pathway is recognized for its prominent role in immune regulation, making it a candidate for therapeutic intervention in transplant tolerance, autoimmune disease, and neuro-inflammation. The company is building upon a deep historical understanding of the CD40/CD40L pathway, as well as preclinical and Phase 1 data, to initiate up to four phase 2 clinical studies with AT-1501. Eledon Pharmaceuticals was founded on March 26, 2004 and is headquartered in Irvine, CA.